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Abstract
Background: Signaling studies in cell lines are hampered by non-physiological alterations obtained in vitro.
Physiologic primary tumor cells from patients with leukemia require passaging through immune-compromised
mice for amplification. The aim was to enable molecular work in patients’ ALL cells by establishing siRNA
transfection into cells amplified in mice.
Results: We established delivering siRNA into these cells without affecting cell viability. Knockdown of single or
multiple genes reduced constitutive or induced protein expression accompanied by marked signaling alterations.
Conclusion: Our novel technique allows using patient-derived tumor cells instead of cell lines for signaling studies
in leukemia.
Introduction
Characterization of intracellular signaling mechanisms is
crucial for the understanding of tumor development and
for the design of novel strategies in anti-tumor therapy.
For practical reasons, signaling studies are mainly per-
formed in cell lines established from human tumors
decades ago and are prone to non-representative muta-
tions [1,2]. Example given, more than 50% of ALL cell
lines inherit mutations of p53, while less than 5% of pri-
mary pediatric samples at initial diagnosis do [3-5].
To overcome these limitations, several groups had
successfully transfected primary leukemia cells. Best
results were obtained in samples from adult patients
with chronic leukemias [6-8]. In contrast, in acute leu-
kemias, rapid onset of therapy impedes repetitive sam-
pling and reliable results of molecular experiments in
primary cells. In pediatric leukemias, small sample
volumes generally disable molecular work on these pri-
mary cells. For the transfection of childhood ALL sam-
ples by nucleofection, so far transgene expression was
studied in detail rendering varying results between 1%
and 62.3% [9].
Acute leukemia samples can be amplified in severely
immuno-compromised mice. The xenograft mouse
model of acute leukemia has been characterized to
enable frequent engraftment with little genetic and phe-
notypic alterations upon passaging through mice [10].
The regular detection of CD surface markers revealed
stable phenotypes over several passages [11].
Here, we describe a new method which will routinely
allow repetitive and reliable molecular signaling studies
on patient-derived childhood ALL cells amplified in
NOD/SCID mice. The aim was to establish a suitable
transfection technique to perform knockdown experi-
ments in patient-derived acute lymphoblastic leukemia
(ALL) cells, instead of ALL cell lines.
Results
We used xenografted cells from n = 11 children with
different subtypes and risk status of ALL (Table 1). All
samples were successfully re-passaged in NOD/SCID
mice, a model with minor clonal selection in ALL [12].
Samples were amplified in mice and used as fresh iso-
lates from different passages without feeder cell co-culti-
vation as frequently seen. Persistence of CD surface
markers was insured by testing before and after passage
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(data not shown).
Optimization of the transfection of patient-derived
childhood ALL cells
Within the many transfection techniques available, elec-
troporation using nucleofection rendered the most out-
standing results in patient-derived ALL cells (data not
shown). To optimize the transfection, 5 million cells
were used within different conditions and protocols cur-
rently used for leukemic cell lines or primary lympho-
cytes. Best results were performed using nucleofection
protocols for primary B- and T-cells. The programs dif-
fer in intensity (increasing from A to X) and the dura-
tion of the electric impulse (increasing from 1 to 25).
Constantly high transfection efficiencies above 90%
combined with low impact on spontaneous apoptosis (<
20% additional apoptosis by transfection) were obtained
using a long pulse of low intensity (program C16) and
the buffers for transfection of normal B- and T-cells
(Figure 1A and 1B). Beyond viability, the absolute num-
ber of viable cells remained unchanged (Figure 1C). The
optimized setting was successfully applied in all n = 11
xenografted patient samples with only marginal varia-
tions in transfection efficiency and cell viability (Figure
1D). Simultaneous transfection of two different siRNA
sequences conjugated to non-overlapping dyes rendered
transfection efficiencies similar to the single transfection
(Figure 1E and data not shown).
The siRNA delivery by nucleofection leads to stable
and reproducible results for a cohort of xenografted
ALL samples.
Efficient knockdown of target genes in patient-derived
ALL cells
We used siRNAs to knock down p53 and its target
genes Caspase-8, NOXA, PUMA and NFkBp65.
Knockdown efficiency was confirmed on protein level in
all samples and all five siRNAs tested rendered reprodu-
cible results (Figure 2A, Additional file 1: Figure S1A
and data no shown). All siRNA sequences had been vali-
dated in JURKAT leukemia cell lines before. siRNAs
were cloned into the pRetro or pSuperior vectors as
shRNAs and were introduced into JURKAT cells by
nucleofection followed by enrichment of transfected
cells using Puromycin. When ever stable expression of
the corresponding shRNA induced a > 90% knockdown
of the target protein, the siRNA induced efficient knock-
down in primary or xenograft cells. The knockdown effi-
ciency was further verified for different siRNA
sequences targeting the identical RNA (Figure 2B). Sta-
bility and reproducibility of the efficiency of the
described technique was verified by repetitive analyses
of xenografted cells from different mice within the iden-
tical passage (Figure 2C) and for different passages (Fig-
ure 2D).
Beyond single targets, successful double knockdown
was obtained by targeting two proteins and yielded a
simultaneously diminished expression of both proteins
(Figure 2E and Additional file 1: Figure S1B). In selected
samples with high viability over prolonged periods of
time in cell culture (> 70% at 120 h), stability of knock-
down was detected for up to 120 h (Figure 2F and data
not shown).
Knockdown of target genes altered signaling in patient-
derived ALL cells
In a next step, the functional impact of the efficient
siRNA delivery for the samples from Figure 2 and Addi-
tional file 1: Figure S1 was tested for the intracellular
apoptosis signaling transduction.
Caspase-8 has been repetitively shown to be essential
for efficient apoptosis induction by the death inducing
ligand TRAIL [13-15]. The functional impact of the
Table 1 Patient characteristics of leukemia samples xenografted in NOD/SCID mice
Sample Isolated
from
Type of
leukemia
Age
(years)
Gender State of
disease
Cytogenetic
characteristics
ALL-50 PB pre-B-ALL 7 f ID n.a.
ALL-53 BM pre-B-ALL 14 f R n.a.
ALL-54 BM pre-B-ALL 3 f ID not aberrant
ALL-177 BM pre-B-ALL 8 f ID TEL/AML1; del12p
ALL-199 BM pre-B-ALL 8 f R trisomy 21
ALL-10S BM pre-B-ALL 4 f ID MLL-AF9 rearrangement
ALL-188 BM pre-B-ALL 9 f ID TEL/AML1
ALL-4S PB T-ALL 4 m ID t(11;14);(p32;q11)
ALL-202 PB T-ALL 9 m ID del9p
ALL-168 BM pre-B-ALL 5 f ID der(19)t(1;19)(q23;p13)
ALL-169 BM pre-B-ALL 18 f ID n.a.
PB peripheral blood, BM bone marrow, (pre-)B-ALL (precursor) B-cell acute lymphoblastic leukemia, T-ALL T-cell acute lymphoblastic leukemia, f female, m male, ID
initial diagnosis, R relapse, n.a. no data available
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ence as depicted in Figure 2A and Additional file 1: Fig-
ure S1A was verified after stimulation with TRAIL in n
= 9 different xenografted samples in at least 3 indepen-
dent experiments which expressed detectable levels of
Caspase-8 (Figure 3). As we had published before, the
efficient knockdown of Caspase-8 and the following sti-
mulation with TRAIL was associated with increased sur-
vival in culture compared to the control cells in some of
the samples investigated [14,15].
Knockdown of target genes alters protein regulation and
function in patient-derived ALL cells
So far, the efficiency of our technique was evaluated for
basal protein expression. In a next step, we evaluated
the effect of siRNA-mediated knockdown on protein
regulation in patient-derived ALL cells.
ALL-168 and ALL-50 showed minor constitutive
expression of Caspase-8 and the expression level was
augmented by the addition of the cytotoxic drug 5-
Fluorouracil according to recent cell line data [13]. On a
functional level, 5-Fluorouracil induced slight upregula-
tion of Caspase-8 and sensitized cells towards TRAIL-
induced apoptosis when TRAIL was applied in high
concentrations. Transfection of siRNA targeting Cas-
pase-8 completely abrogated 5-Fluorouracil-induced
upregulation of Caspase-8 in patient-derived ALL-50
and ALL-168 cells. In the absence of upregulation of
Caspase-8 due to transfection of Caspase-8 targeting
siRNA, Fluorouracil was no longer capable to sensitize
t o w a r d sT R A I L - i n d u c e da p o p t o s i s( F i g u r e4a n dA d d i -
tional file 1: Figure S2).
On a broader level, these data prove that efficient
siRNA delivery in patient-derived childhood ALL cells
induces significant functional alterations which can be
achieved either upon knockdown of constitutively
expressed genes or by inhibition of protein regulation.
Taken together, we have successfully established a
method allowing reliable RNAi-based signaling studies
in patient-derived pediatric ALL cells.
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Figure 1 Optimization of the transfection efficiency of patient-derived childhood ALL cells. A) ALL cells of patient ALL-50 were
xenografted and amplified in NOD/SCID mice, isolated from spleens and transfected by nucleofection with a control siRNA oligonucleotide
conjugated to Alexa-Fluor-488 using different programs. After 48 h of in vitro culture, apoptosis was measured by forward side scatter analysis
and transfection efficiency in living cells by the shift of fluorescence intensity in channel 1 in FACscan. Presented are original results of 4
different transfection conditions for sample ALL-50. B) The data of eight different transfection conditions (X-Axis indicates the different programs
offered by the company) are summarized for transfection efficiency and impact of transfection on survival of ALL cells for sample ALL-50. *
highlights the program used for further experiments. C) Absolute cell count was determined in ALL-50 cells untreated (co) and transfected with
the dye-conjugated control sequence (sicontrol) at 0 and 48 h. D) Transfection efficiency and cell viability was determined in overall n = 11
different xenograft samples using program C16 as in Figure 1B. E) ALL cells from patient ALL-50 were simultaneously transfected with a control
siRNA against Lamin conjugated to Alexa-Fluor-488 and siRNA control oligonucleotide conjugated to Alexa-Fluor647 as in Figure 1B using
program C16.
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Figure 2 Efficient knockdown of target genes in patient-derived childhood ALL-cells. A) ALL cells from sample ALL-53, ALL-50, ALL-168
and ALL-169 were transfected with siRNA against Caspase 8, p53 or NFBp65 as in Figure 1C. Cells were harvested 48 h after transfection and
Western Blot analysis of total cellular protein was performed. GAPDH served as loading control. Where indicated, xenograft samples did express
only low levels of Caspase-8. B) ALL cells from sample ALL-53 (left panel) and ALL-54 (right panel) were transfected as in Figure 2A using two
different siRNA sequences targeting Caspase-8. C) ALL cells of sample ALL-199 were repetitively xenografted within the identical passage (p6)
and treated and analyzed as in Figure 2A. D) ALL cells of sample ALL-54 were xenografted in passage 3 (upper panel) and 4 (lower panel) and
treated and analyzed as in Figure 2A. E). ALL cells from sample ALL-50 were simultaneously transfected and analyzed as in Figure 2A using
siRNAs against NOXA and PUMA. F). ALL-199 (upper panel) and ALL-54 (lower panel) were transfected with siRNA against p53 as in Figure 2A
and analyzed at 48 and 120 h for the stability of the knockdown.
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cells
So far primary childhood ALL cells were only used after
xenograft transplantation due to the usually limited
number of cells available. As proof of principle, we per-
formed the identical experimental procedure in primary
childhood T-ALL cells isolated from peripheral blood of
a 8 year old girl at initial diagnosis. Using a dye-conju-
gated control siRNAnucleofected with program C16, we
were able to demonstrate a comparable transfection effi-
ciency, high viability of the cells and unchanged absolute
cell count comparable to the xenograft experiments
(Figure 5A-C). Similarly, siRNA transfection using siR-
NAs against Caspase-8, p53 and NFB rendered effi-
cient knock-down of target proteins (Figure 5D)
accompanied by marked functional alterations studied
using Caspase-8 and TRAIL (Figure 5E).
The data obtained in this primary ALL sample suggest
that the described technique is well applicable not only
to xenografted primary ALL cells but although to at
least some primary ALL samples.
Conclusions
We present a novel method allowing repetitive molecu-
lar signaling studies in pediatric ALL cells from indivi-
dual children. The focus of our method are studies of
signaling pathways which are not adequately modeled in
ALL cell lines and require patient-derived tumor cells,
such as the p53 network. The combination of amplifica-
tion of these cells in immune-incompetent mice and the
presented transfection technique allows molecular sig-
naling studies (i) in patient-derived pediatric samples,
where small volumes are notoriously restrictive; (ii) in
cells which resemble primary tumor cells substantially
better than established cell lines do [11,12]; (iii) repeti-
tively on highly viable cells allowing reliable results. To
return to the discussed difficulty of p53 signaling studies
in leukemia cell lines, the presented technique will
enable routine investigation of primary childhood ALL
cells that have been performed so far mainly in child-
hood ALL cell lines with restricted relevance to the clin-
ical setting due to inherited mutations i.e. in CEM and
JURKAT leukemia cells [13,16].
U p o ni s o l a t i o nf r o ms p l e e no rb o n em a r r o wo fm i c e ,
patient-derived cells can be used freshly for repetitive
experiments and show better viability compared to pri-
mary samples due to more favorable handling and ship-
ping. To our experience, cell viability is sufficient for
transfection experiments in the majority of patient-
derived samples freshly isolated from mice. The data
obtained in the primary childhood ALL sample suggest
s
p
e
c
i
f
i
c
s
u
r
v
i
v
a
l
 
 
 
 
 
 
 
 
 
 
a
p
o
p
t
o
s
i
s
 
(
%
)
100
75
50
25
0
-25
sicontrol
siCasp-8 * * *
*
* *
* * NS
Figure 3 Functional impact of the efficient siRNA interference.
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in Figure 2A and Additional file 1: Figure S1A and stimulated with
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< 0.05, paired t-test, NS = not significant.
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Figure 4 Efficient inhibition of protein regulation.A L Lc e l l so f
patient ALL-50 were transfected as in Figure 1C with a non-specific
sequence (sicontrol) or siRNA against Caspase-8 (Casp-8) followed
by stimulation with 5-Fluorouracil (5-FU; 30 μM) and TRAIL (1 μg/
ml)) 6 h later for another 72 h. In parallel, Western Blot analysis was
performed of cells incubated with 5-FU for 48 h. GAPDH served as
loading control. One representative blot is shown. Depicted are
mean values and SD of 4 independent experiments performed in
duplicates. *p < 0.05, paired t-test, combined stimulation compared
to the additive result of both single agents, NS = not significant.
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Page 5 of 8that the described technique is as well applicable to
freshly isolated primary ALL samples. It remains to be
tested, whether our method generally facilitates
transfection of freshly isolated, primary ALL cells, e.g.
from adult patients and other types of primary leukemia
cells which were not studied so far using this technique.
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Figure 5 Applicability of the described technique to primary patient-derived childhood ALL-cells. A-C)Freshly isolated ALL cells from a 8
year old girl at initial diagnosis of T-ALL were transfected and analyzed as in Figure 1A-C. D) Primary ALL cells from Figure 5A were transfected
with specific siRNAs as in Figure 2A. E) Primary ALL cells from Figure 5A were transfected and stimulated with TRAIL as in Figure 3.
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Materials
TRAIL was obtained from PeproTech (Hamburg, Ger-
many), all further reagents were obtained from Sigma-
Aldrich (St. Louis, MO). For Western Blot analysis, the
following antibodies were used: anti NFBp65 and anti
p53 from Santa Cruz Biotechnology Inc. (Santa Cruz,
CA); anti PUMA from Cell Signaling Technology Inc.
(Danvers, MA); anti GAPDH from Thermo Fisher (Wal-
tham, MA); anti NOXA from Calbiochem (San Diego,
CA); anti Caspase-8 from Alexis Corp. (Lausen,
Switzerland).
For flow cytometric analysis of CD surface marker sta-
bility, the following antibodies were used: anti CD4-PE
from DAKO (Hamburg, Germany), anti CD5-PeCy5.5,
anti CD7-APC, anti CD10-APC, anti CD19-PeCy5.5,
anti CD22-PE and anti HLA-DR-PeCy5.5 from Life
Technologies (Darmstadt, Germany), anti CD19-FITC,
anti CD20-FITC, anti CD34-PE and anti CD38-PE from
BD Biosciences (San Jose, CA).
Amplification of primary childhood ALL cells in NOD/SCID
mice
Informed consent was obtained from all patients and
experiments were performed according to the declara-
tion of Helsinki as approved in written form by the ethi-
cal committee of the medical faculty of the Ludwig
Maximilians University Munich (LMU 068-08) and the
Children’s Hospital of the TU Munich (TU 2115/08).
Primary ALL blasts were obtained from children treated
at the Ludwig Maximilians University Children’sH o s p i -
tal or the children’s hospital of the TU Munich. Tumor
cells were isolated from blood or bone marrow samples.
Animal work was approved by the Regierung von
Oberbayern (55.2-1-54-2531-2-07). The xenograft NOD/
SCID mouse model was performed as described by
others [17-19]. Fresh primary childhood ALL cells were
isolated by Ficoll gradient centrifugation for 30 min at
500 g from peripheral blood or bone marrow aspirates
that had been obtained from leftovers of clinical routine
sampling followed by two washing steps in PBS before
resuspension in cell culture medium. 10 million ALL
cells were injected into 6-8 weeks old NOD/SCID mice
via the tail vain. Engraftment was monitored by flow
cytometry and measurement of human cells in periph-
eral blood. Engrafted human ALL cells were isolated
from spleens of diseased mice by pressing through a cell
strainer (BD Biosciences) and Ficoll gradient centrifuga-
tion. Cells were separated and simultaneously injected
into next generation of mice and subjected to in vitro
experiments. Regular detection of CD surface markers
revealed stable phenotypes of the samples over all pas-
sages [11].
Transfection and stimulation of patient-derived ALL cells
For nucleofection (AmaxaNucleofector, Lonza, Basel,
Switzerland), 5 million cells were used per reaction.
Patient-derived ALL cells were resuspended in 100 μl
pre-warmed buffer from the nucleofector kit for human
B/T-cells plus 5 μlsiRNA oligonucleotides (20 μM). The
following siRNAs were used: silencer validated siRNA
against p53 (5’-GGGUUAGUUUACAAUCAGC-3’,
Ambion, Austin, TX), siRNA against NOXA (5’-GUC-
GAGUGUGCUACUCAACU-3’); siRNA against PUMA
(5’-UCUCAUCAUGGGACUCCUG-3’;s i R N Aa g a i n s t
Caspase-8 (5’-GCUCUUCC GAAUUAAUAGATT-3’,
second siRNA against Caspase 8 (siCasp8_2; 5’-GCU-
CUUCCGAAUUAAUAGATT-3’) and siRNA against
NFBp65 (all from MWG Biotech, Ebersberg, Germany)
and All Star negative control siRNA conjugated with
Alexa-Fluor-488 or Alexa-Fluor-647 (Qiagen, Hilden,
Germany). For double transfections, siRNA against
lamin conjugated to Alexa-Fluor-488 (analyzed in FITC
channel) and negative control siRNA conjugated with
Alexa-Fluor-647 (APC-channel) was analyzed using a
LSR II flow cytometer (BD Biosciences) and FlowJo
(TreeStar, Ashland, OR) software version 8.3. After
transfection, cells were incubated 5 min at room tem-
perature in the nucleofection cuvette, then transferred
to 5 ml pre-warmed RPMI medium supplemented with
20% FCS, 1% penicillin/streptomycin, 1% gentamycin, 6
μl/ml mixture of insulin, transferrin and selenium (Invi-
trogen, Carlsbad, CA), 1 mM sodium pyruvate and 50
μM 1-thioglycerole (Sigma-Aldrich, St. Louis, MO).
After transfection with fluorochrome-conjugated nega-
tive control siRNA, cells were washed twice in PBS
prior to flow cytometric determination of transfection
efficiency. Stimulation experiments were started 6 or 48
h after transfection.
Western blot and measurement of apoptosis
Western Blot analysis was performed out of total cellu-
lar lysates using the following total cell lysis buffer: 20
mMTris-HCl (pH 7.5), 150 mMNaCl, 1 mM Na2EDTA,
1 mM EGTA, 1% Triton, 2.5 mM sodium pyropho-
sphate, 1 mM beta-glycerophosphate, 1 mM Na3VO4
supplemented with 10 μg/ml protease inhibitor cocktail
set I (Calbiochem). Lysates were separated by SDS-page
gel electrophoresis followed by transfer onto a nitrocel-
lulose membrane and detection of the primary antibody
by a HRP-conjugated secondary antibody. Apoptosis was
measured by forward side scatter analysis and precision
of this technique confirmed by Annexin V and propi-
dium iodide double staining according to the manufac-
turers instructions using FACscan or LSR II flow
cytometry and Cell Quest Pro (BD Biosciences) software
version 3.2.1.
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Page 7 of 8Statistical analysis
Specific apoptosis was calculated as [(apoptosis of sti-
mulated cells at end point minus apoptosis of unstimu-
lated cells at end point) divided by (100 minus apoptosis
of unstimulated cells at end point) times 100]. When-
ever indicated, paired t-test was performed to detect sta-
tistically significant differences out of at least three
independent experiments with two technical replicates.
Statistical significance was accepted with p-values <
0.05.
Additional material
Additional file 1: Figure S1. Efficient knockdown of target genes in
patient-derived childhood ALL-cells ALL cells from n = 7 further patients
were transfected as in Figure 2A. ALL cells from sample ALL-169 were
treated and analyzed as in Figure 2E. Figure S2. Efficient inhibition of
protein regulation. ALL-168 cells were treated and analyzed as in Figure
4. Statistical analysis was performed out of n = 8 independent
experiments. p < 0.05, paired t-test, NS = not significant.
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